RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

Japanese patients with vitiligo experienced lower quality of life and higher levels of anxiety and depression, especially when the disease affected their social life or had relapsed, according to a ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...